Request Free Sample ×
Companion Diagnostics Market Research Report - Forecast Till 2035 Infographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Companion Diagnostic Market

ID: MRFR/MED/2231-CR
168 Pages
Satyendra Maurya
Last Updated: April 15, 2026

Companion Diagnostics Market Research Report Information by Test Type (HER2 Testing, PD-1 Testing, EGFR Mutation Testing, ALK Rearrangement Testing, and Others), By Product & Services (assays, reagents & kits, instruments/systems, and software & services), By Technology (polymerase chain reaction (PCR), next-generation sequencing (NGS), immunohistochemistry (IHC), Fluorescence In-Situ Hybridization (FISH), and others),By Indication (cancer, neurological disorders, cardiovascular disorders, and infectious diseases), By End User (Biopharmaceutical and Biotechnology Companies, CROs and CDMOs, and Others) By Region (North America, Europe, Asia-Pacific) - Forecast to 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Companion Diagnostic Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Methodology Download PDF
  1. 1 EXECUTIVE SUMMARY
  2. 2 MARKET INTRODUCTION
    1. 2.1 DEFINITION
    2. 2.2 SCOPE OF THE STUDY
    3. 2.3 RESEARCH OBJECTIVE
    4. 2.4 MARKET STRUCTURE
  3. 3 RESEARCH METHODOLOGY
    1. 3.1 OVERVIEW
    2. 3.2 DATA FLOW
      1. 3.2.1 Data Mining Process
    3. 3.3 PURCHASED DATABASE:
    4. 3.4 SECONDARY SOURCES:
      1. 3.4.1 Secondary Research data flow:
    5. 3.5 PRIMARY RESEARCH:
      1. 3.5.1 Primary Research Data Flow:
      2. 3.5.2 Primary Research: Number of Interviews conducted
    6. 3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
      1. 3.6.1 Revenue Analysis Approach
    7. 3.7 DATA FORECASTING
      1. 3.7.1 Data forecasting Type
    8. 3.8 DATA MODELING
      1. 3.8.1 microeconomic factor analysis:
      2. 3.8.2 Data modeling:
    9. 3.9 TEAMS AND ANALYST CONTRIBUTION
  4. 4 MARKET DYNAMICS
    1. 4.1 INTRODUCTION
    2. 4.2 DRIVERS
      1. 4.2.1 Rising Cancer & Chronic Disease Prevalence
      2. 4.2.2 Growing Adoption of Targeted Therapies and Precision Medicine
      3. 4.2.3 Technological Advances
      4. 4.2.4 Increasing Drug–Diagnostic Co-Development & Regulatory Approvals
    3. 4.3 RESTRAINTS
      1. 4.3.1 High Cost & Capital Investment for CDx Development and Testing
      2. 4.3.2 Regulatory Complexity and Varied Approval Pathways
      3. 4.3.3 Limited Reimbursement, Uneven Access & Awareness
    4. 4.4 OPPORTUNITIES
      1. 4.4.1 Expansion beyond oncology into other therapeutic areas
      2. 4.4.2 Growth in bioinformatics, software & services supporting CDx
  5. 5 MARKET FACTOR ANALYSIS
    1. 5.1 PORTER'S FIVE FORCES MODEL
      1. 5.1.1 Threat of New Entrants
      2. 5.1.2 BARGAINING POWER OF SUPPLIERS
      3. 5.1.3 Threat of Substitutes
      4. 5.1.4 Bargaining Power of Buyers
      5. 5.1.5 Intensity of Rivalry
    2. 5.2 IMPACT ANALYSIS OF COVID-19
      1. 5.2.1 Disruption in Diagnostic Testing and Oncology Procedures
      2. 5.2.2 Supply Chain Disruptions
      3. 5.2.3 Changes in Patient Behavior and Clinical Workflows
      4. 5.2.4 Impact on R&D and Innovation
    3. 5.3 COMPANION DIAGNOSTIC ANALYSIS FOR KEYTRUDA, TECENTRIQ, AND LIBTAYO
    4. 5.4 PDL1 SALES DATA GLOBALLY, 2019-2035 (USD MILLION)
    5. 5.5 MARKET SHARE BY DRUG GLOBAL, REGIONAL AND COUNTRY LEVEL 2024 (%)
      1. 5.5.1 GLOBAL MARKET SHARE BY DRUG, 2024 (%)
      2. 5.5.2 North America MARKET SHARE BY DRUG, 2024 (%)
        1. 5.5.2.1 US MARKET SHARE BY DRUG, 2024 (%)
      3. 5.5.3 Europe MARKET SHARE BY DRUG, 2024 (%)
        1. 5.5.3.1 GERMANY MARKET SHARE BY DRUG, 2024 (%)
        2. 5.5.3.2 UK MARKET SHARE BY DRUG, 2024 (%)
      4. 5.5.4 ASIA-PACIFIC MARKET SHARE BY DRUG, 2024 (%)
        1. 5.5.4.1 CHINA MARKET SHARE BY DRUG, 2024 (%)
        2. 5.5.4.2 INDIA MARKET SHARE BY DRUG, 2024 (%)
        3. 5.5.4.3 JAPAN MARKET SHARE BY DRUG, 2024 (%)
    6. 5.6 MARKET SHARE BY CLONE GLOBAL, REGIONAL AND COUNTRY LEVEL 2024 (%)
      1. 5.6.1 GLOBAL MARKET SHARE BY clone, 2024 (%)
      2. 5.6.2 North America MARKET SHARE BY CLONE, 2024 (%)
        1. 5.6.2.1 US MARKET SHARE BY CLONE, 2024 (%)
      3. 5.6.3 EUROPE MARKET SHARE BY CLONE, 2024 (%)
        1. 5.6.3.1 GERMANY MARKET SHARE BY CLONE, 2024 (%)
        2. 5.6.3.2 UK MARKET SHARE BY CLONE, 2024 (%)
      4. 5.6.4 ASIA-PACIFIC MARKET SHARE BY CLONE, 2024 (%)
        1. 5.6.4.1 INDIA MARKET SHARE BY CLONE, 2024 (%)
        2. 5.6.4.2 JAPAN MARKET SHARE BY CLONE, 2024 (%)
    7. 5.7 QUALITATIVE ANALYSIS OF PD-L1 TESTING CUT-OFFS
    8. 5.8 PDL1 SALES DATA GLOBALLY, (2019-2035), BY APPLICATION
    9. 5.9 PRICING ANALYSIS, 2024 (USD)
  6. 6 GLOBAL COMPANION DIAGNOSTICS MARKET, BY TEST TYPE
    1. 6.1 OVERVIEW
    2. 6.2 HER2 TESTING
    3. 6.3 PD-1 TESTING
    4. 6.4 EGFR MUTATION TESTING
    5. 6.5 ALK REARRANGEMENT TESTING
    6. 6.6 OTHERS
  7. 7 GLOBAL COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES
    1. 7.1 OVERVIEW
    2. 7.2 ASSAYS, REAGENTS & KITS
    3. 7.3 INSTRUMENTS/SYSTEMS
    4. 7.4 SOFTWARE & SERVICES
  8. 8 GLOBAL COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY
    1. 8.1 OVERVIEW
    2. 8.2 POLYMERASE CHAIN REACTION (PCR)
    3. 8.3 NEXT-GENERATION SEQUENCING (NGS)
    4. 8.4 IMMUNOHISTOCHEMISTRY (IHC)
    5. 8.5 FLUORESCENCE IN-SITU HYBRIDIZATION (FISH)
    6. 8.6 OTHERS
  9. 9 GLOBAL COMPANION DIAGNOSTICS MARKET, BY INDICATION
    1. 9.1 OVERVIEW
    2. 9.2 CANCER
    3. 9.3 NEUROLOGICAL DISORDERS
    4. 9.4 CARDIOVASCULAR DISORDERS
    5. 9.5 INFECTIOUS DISEASES
  10. 10 GLOBAL COMPANION DIAGNOSTICS MARKET, BY END USER
    1. 10.1 OVERVIEW
    2. 10.2 BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
    3. 10.3 CROS AND CDMOS
    4. 10.4 OTHERS
  11. 11 GLOBAL COMPANION DIAGNOSTICS MARKET, BY REGION
    1. 11.1 OVERVIEW
    2. 11.2 NORTH AMERICA
      1. 11.2.1 US
      2. 11.2.2 CANADA
    3. 11.3 EUROPE
      1. 11.3.1 GERMANY
      2. 11.3.2 france
      3. 11.3.3 UK
      4. 11.3.4 ITALY
      5. 11.3.5 Spain
      6. 11.3.6 Denmark
      7. 11.3.7 Finland
      8. 11.3.8 Iceland
      9. 11.3.9 Norway
      10. 11.3.10 Sweden
      11. 11.3.11 Rest of Europe
    4. 11.4 ASIA-PACIFIC
      1. 11.4.1 India
      2. 11.4.2 Japan
      3. 11.4.3 South Korea
      4. 11.4.4 Australia
      5. 11.4.5 Rest of Asia-Pacific
  12. 12 COMPETITIVE LANDSCAPE
    1. 12.1 INTRODUCTION
    2. 12.2 MARKET SHARE ANALYSIS, 2024
    3. 12.3 COMPETITOR DASHBOARD
    4. 12.4 PUBLIC PLAYERS STOCK SUMMARY
    5. 12.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL
    6. 12.1 KEY DEVELOPMENTS & GROWTH STRATEGIES
      1. 12.1.1 Product/service launch
      2. 12.1.2 acquisition
      3. 12.1.3 Accreditation
      4. 12.1.4 Collaboration/ Partnership
  13. 13 COMPANY PROFILES
    1. 13.1 QIAGEN
      1. 13.1.1 COMPANY OVERVIEW
      2. 13.1.2 FINANCIAL OVERVIEW
      3. 13.1.3 products OFFERed
      4. 13.1.4 KEY DEVELOPMENTS
      5. 13.1.5 SWOT ANALYSIS
      6. 13.1.6 KEY STRATEGIES
      7. 13.2.4 products OFFERed
      8. 13.2.6 SWOT ANALYSIS
    2. 13.3 BIOMÉRIEUX
      1. 13.3.1 COMPANY OVERVIEW
      2. 13.3.2 FINANCIAL OVERVIEW
      3. 13.3.3 products OFFERed
      4. 13.3.4 KEY DEVELOPMENTS
      5. 13.3.5 SWOT ANALYSIS
      6. 13.3.6 KEY STRATEGIES
    3. 13.4 LEICA BIOSYSTEMS NUSSLOCH GMBH
      1. 13.4.1 COMPANY OVERVIEw
      2. 13.4.2 FINANCIAL OVERVIEW
      3. 13.4.3 products OFFERed
      4. 13.4.4 KEY DEVELOPMENTS
      5. 13.4.5 KEY STRATEGIES
    4. 13.5 NG BIOTECH
      1. 13.5.1 COMPANY OVERVIEW
      2. 13.5.2 FINANCIAL OVERVIEW
      3. 13.5.3 products OFFERed
      4. 13.5.5 KEY STRATEGIES
    5. 13.6 THERMO FISHER SCIENTIFIC INC.
      1. 13.6.1 COMPANY OVERVIEW
      2. 13.6.2 FINANCIAL OVERVIEW
      3. 13.6.3 products OFFERed
      4. 13.6.4 KEY DEVELOPMENTs
      5. 13.6.5 SWOT ANALYSIS
      6. 13.6.6 Key Strategy
    6. 13.7 ILLUMINA, INC.
      1. 13.7.1 COMPANY OVERVIEW
      2. 13.7.2 FINANCIAL OVERVIEW
      3. 13.7.3 PRODUCTS OFFERed
      4. 13.7.4 KEY DEVELOPMENTS
      5. 13.7.5 KEY STRATEGIES
    7. 13.8 AGILENT TECHNOLOGIES, INC.
      1. 13.8.1 COMPANY OVERVIEW
      2. 13.8.2 FINANCIAL OVERVIEW
      3. 13.8.3 PRODUCTS OFFERED
      4. 13.8.4 KEY DEVELOPMENTS
      5. 13.8.5 SWOT ANALYSIS
      6. 13.8.6 KEY STRATEGIES
    8. 13.9 FOUNDATION MEDICINE INC. (F. HOFFMANN-LA ROCHE LTD )
      1. 13.9.1 COMPANY OVERVIEW
      2. 13.9.2 FINANCIAL OVERVIEW
      3. 13.9.3 productS OFFERED
      4. 13.9.4 KEY DEVELOPMENTs
      5. 13.9.5 KEY STRATEGIES
    9. 13.10 MYRIAD GENETICS, INC.
      1. 13.10.1 COMPANY OVERVIEW
      2. 13.10.2 FINANCIAL OVERVIEW
      3. 13.10.3 productS OFFERED
      4. 13.10.4 KEY DEVELOPMENTs
      5. 13.10.5 KEY STRATEGIES
  14. 14 DATA CITATIONS
    1.  
  15. LIST OF TABLES
  16. TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT
  17. TABLE 2 COMPANION DIAGNOSTIC ANALYSIS FOR KEYTRUDA, TECENTRIQ, AND LIBTAYO
  18. TABLE 3 PDL1 SALES DATA GLOBALLY, 2019-2035 (USD MILLION)
  19. TABLE 4 PD-L1 TESTING CUT-OFFS
  20. TABLE 5 PDL1 SALES DATA GLOBALLY, (2019-2035), BY APPLICATION
  21. TABLE 6 PRICING ANALYSIS, 2024 (USD)
  22. TABLE 7 GLOBAL COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2024 & 2035 (USD MILLION)
  23. TABLE 8 GLOBAL COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2024 & 2035 (TEST VOLUME)
  24. TABLE 9 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TEST TYPE, 2024 & 2035 (USD MILLION)
  25. TABLE 10 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TEST TYPE, 2024 & 2035 (TEST VOLUME)
  26. TABLE 11 GLOBAL COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICES, 2024 & 2035 (USD MILLION)
  27. TABLE 12 GLOBAL COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024 & 2035 (USD MILLION)
  28. TABLE 13 GLOBAL COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024 & 2035 (USD MILLION)
  29. TABLE 14 GLOBAL COMPANION DIAGNOSTICS MARKET, BY END USER, 2024 & 2035 (USD MILLION)
  30. TABLE 15 GLOBAL COMPANION DIAGNOSTICS MARKET, BY REGION, 2019-2035 (USD MILLION)
  31. TABLE 16 GLOBAL COMPANION DIAGNOSTICS MARKET, BY REGION, 2019-2035 (TEST VOLUME)
  32. TABLE 17 NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2019-2035 (USD MILLION)
  33. TABLE 18 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (USD MILLION)
  34. TABLE 19 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (TEST VOLUME)
  35. TABLE 20 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-2035 (USD MILLION)
  36. TABLE 21 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-2035 (TEST VOLUME)
  37. TABLE 22 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICES, 2019-2035 (USD MILLION)
  38. TABLE 23 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2035 (USD MILLION)
  39. TABLE 24 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-2035 (USD MILLION)
  40. TABLE 25 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-2035 (USD MILLION)
  41. TABLE 26 US: COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (USD MILLION)
  42. TABLE 27 US: COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (TEST VOLUME)
  43. TABLE 28 US: COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-2035 (USD MILLION)
  44. TABLE 29 US: COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-2035 (TEST VOLUME)
  45. TABLE 30 US: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICES, 2019-2035 (USD MILLION)
  46. TABLE 31 US: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2035 (USD MILLION)
  47. TABLE 32 US: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-2035 (USD MILLION)
  48. TABLE 33 US: COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-2035 (USD MILLION)
  49. TABLE 34 CANADA: COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (USD MILLION)
  50. TABLE 35 CANADA: COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (TEST VOLUME)
  51. TABLE 36 CANADA: COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-2035 (USD MILLION)
  52. TABLE 37 CANADA: COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-2035 (TEST VOLUME)
  53. TABLE 38 CANADA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICES, 2019-2035 (USD MILLION)
  54. TABLE 39 CANADA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2035 (USD MILLION)
  55. TABLE 40 CANADA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-2035 (USD MILLION)
  56. TABLE 41 CANADA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-2035 (USD MILLION)
  57. TABLE 42 EUROPE: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2019-2035 (USD MILLION)
  58. TABLE 43 EUROPE COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2019-H-2035 (TEST VOLUME)
  59. TABLE 44 EUROPE COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (USD MILLION)
  60. TABLE 45 EUROPE COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (TEST VOLUME)
  61. TABLE 46 EUROPE COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION)
  62. TABLE 47 EUROPE COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME)
  63. TABLE 48 EUROPE COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION)
  64. TABLE 49 EUROPE COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION)
  65. TABLE 50 EUROPE COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION)
  66. TABLE 51 EUROPE COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION)
  67. TABLE 52 GERMANY COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (USD MILLION)
  68. TABLE 53 GERMANY COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (TEST VOLUME)
  69. TABLE 54 GERMANY COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION)
  70. TABLE 55 GERMANY COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME)
  71. TABLE 56 GERMANY COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION)
  72. TABLE 57 GERMANY COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION)
  73. TABLE 58 GERMANY COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION)
  74. TABLE 59 GERMANY COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION)
  75. TABLE 60 FRANCE COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (USD MILLION)
  76. TABLE 61 FRANCE COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (TEST VOLUME)
  77. TABLE 62 FRANCE COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION)
  78. TABLE 63 FRANCE COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME)
  79. TABLE 64 FRANCE COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION)
  80. TABLE 65 FRANCE COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION)
  81. TABLE 66 FRANCE COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION)
  82. TABLE 67 FRANCE COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION)
  83. TABLE 68 UK COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (USD MILLION)
  84. TABLE 69 UK COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (TEST VOLUME)
  85. TABLE 70 UK COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION)
  86. TABLE 71 UK COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME)
  87. TABLE 72 UK COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION)
  88. TABLE 73 UK COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION)
  89. TABLE 74 UK COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION)
  90. TABLE 75 UK COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION)
  91. TABLE 76 ITALY COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (USD MILLION)
  92. TABLE 77 ITALY COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (TEST VOLUME)
  93. TABLE 78 ITALY COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION)
  94. TABLE 79 ITALY COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME)
  95. TABLE 80 ITALY COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION)
  96. TABLE 81 ITALY COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION)
  97. TABLE 82 ITALY COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION)
  98. TABLE 83 ITALY COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION)
  99. TABLE 84 SPAIN COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (USD MILLION)
  100. TABLE 85 SPAIN COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (TEST VOLUME)
  101. TABLE 86 SPAIN COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION)
  102. TABLE 87 SPAIN COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME)
  103. TABLE 88 SPAIN COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION)
  104. TABLE 89 SPAIN COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION)
  105. TABLE 90 SPAIN COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION)
  106. TABLE 91 SPAIN COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION)
  107. TABLE 92 DENMARK COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (USD MILLION)
  108. TABLE 93 DENMARK COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (TEST VOLUME)
  109. TABLE 94 DENMARK COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION)
  110. TABLE 95 DENMARK COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME)
  111. TABLE 96 DENMARK COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION)
  112. TABLE 97 DENMARK COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION)
  113. TABLE 98 DENMARK COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION)
  114. TABLE 99 DENMARK COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION)
  115. TABLE 100 FINLAND COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (USD MILLION)
  116. TABLE 101 FINLAND COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (TEST VOLUME)
  117. TABLE 102 FINLAND COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION)
  118. TABLE 103 FINLAND COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME)
  119. TABLE 104 FINLAND COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION)
  120. TABLE 105 FINLAND COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION)
  121. TABLE 106 FINLAND COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION)
  122. TABLE 107 FINLAND COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION)
  123. TABLE 108 ICELAND COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (USD MILLION)
  124. TABLE 109 ICELAND COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (TEST VOLUME)
  125. TABLE 110 ICELAND COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION)
  126. TABLE 111 ICELAND COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME)
  127. TABLE 112 ICELAND COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION)
  128. TABLE 113 ICELAND COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION)
  129. TABLE 114 ICELAND COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION)
  130. TABLE 115 ICELAND COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION)
  131. TABLE 116 NORWAY COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (USD MILLION)
  132. TABLE 117 NORWAY COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (TEST VOLUME)
  133. TABLE 118 NORWAY COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION)
  134. TABLE 119 NORWAY COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME)
  135. TABLE 120 NORWAY COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION)
  136. TABLE 121 NORWAY COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION)
  137. TABLE 122 NORWAY COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION)
  138. TABLE 123 NORWAY COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION)
  139. TABLE 124 SWEDEN COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (USD MILLION)
  140. TABLE 125 SWEDEN COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (TEST VOLUME)
  141. TABLE 126 SWEDEN COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION)
  142. TABLE 127 SWEDEN COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME)
  143. TABLE 128 SWEDEN COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION)
  144. TABLE 129 SWEDEN COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION)
  145. TABLE 130 SWEDEN COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION)
  146. TABLE 131 SWEDEN COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION)
  147. TABLE 132 REST OF EUROPE COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (USD MILLION)
  148. TABLE 133 REST OF EUROPE COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (TEST VOLUME)
  149. TABLE 134 REST OF EUROPE COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION)
  150. TABLE 135 REST OF EUROPE COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME)
  151. TABLE 136 REST OF EUROPE COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION)
  152. TABLE 137 REST OF EUROPE COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION)
  153. TABLE 138 REST OF EUROPE COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION)
  154. TABLE 139 REST OF EUROPE COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION)
  155. TABLE 140 ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2019-2035 (USD MILLION)
  156. TABLE 141 ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2019-2035 (TEST VOLUME)
  157. TABLE 142 ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (USD MILLION)
  158. TABLE 143 ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (TEST VOLUME)
  159. TABLE 144 ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING , BY TYPE, 2019-H-2035 (USD MILLION)
  160. TABLE 145 ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME)
  161. TABLE 146 ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION)
  162. TABLE 147 ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION)
  163. TABLE 148 ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION)
  164. TABLE 149 ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION)
  165. TABLE 150 INDIA COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (USD MILLION)
  166. TABLE 151 INDIA COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (TEST VOLUME)
  167. TABLE 152 INDIA COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING , BY TYPE, 2019-H-2035 (USD MILLION)
  168. TABLE 153 INDIA COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME)
  169. TABLE 154 INDIA COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION)
  170. TABLE 155 INDIA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION)
  171. TABLE 156 INDIA COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION)
  172. TABLE 157 INDIA COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION)
  173. TABLE 158 JAPAN COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (USD MILLION)
  174. TABLE 159 JAPAN COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (TEST VOLUME)
  175. TABLE 160 JAPAN COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING , BY TYPE, 2019-H-2035 (USD MILLION)
  176. TABLE 161 JAPAN COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME)
  177. TABLE 162 JAPAN COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION)
  178. TABLE 163 JAPAN COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION)
  179. TABLE 164 JAPAN COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION)
  180. TABLE 165 JAPAN COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION)
  181. TABLE 166 SOUTH KOREA COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (USD MILLION)
  182. TABLE 167 SOUTH KOREA COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (TEST VOLUME)
  183. TABLE 168 SOUTH KOREA COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING , BY TYPE, 2019-H-2035 (USD MILLION)
  184. TABLE 169 SOUTH KOREA COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME)
  185. TABLE 170 SOUTH KOREA COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION)
  186. TABLE 171 SOUTH KOREA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION)
  187. TABLE 172 SOUTH KOREA COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION)
  188. TABLE 173 SOUTH KOREA COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION)
  189. TABLE 174 AUSTRALIA COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (USD MILLION)
  190. TABLE 175 AUSTRALIA COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (TEST VOLUME)
  191. TABLE 176 AUSTRALIA COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION)
  192. TABLE 177 AUSTRALIA COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME)
  193. TABLE 178 AUSTRALIA COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION)
  194. TABLE 179 AUSTRALIA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION)
  195. TABLE 180 AUSTRALIA COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION)
  196. TABLE 181 AUSTRALIA COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION)
  197. TABLE 182 REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (USD MILLION)
  198. TABLE 183 REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (TEST VOLUME)
  199. TABLE 184 REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING , BY TYPE, 2019-H-2035 (USD MILLION)
  200. TABLE 185 REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME)
  201. TABLE 186 REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION)
  202. TABLE 187 REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION)
  203. TABLE 188 REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION)
  204. TABLE 189 REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION)
  205. TABLE 190 PRODUCT/SERVICE LAUNCH
  206. TABLE 191 ACQUISITION/EXPANSION
  207. TABLE 192 ACCREDITATION
  208. TABLE 193 COLLABORATION/ PARTNERSHIP
  209. TABLE 194 QIAGEN: PRODUCTS AND SERVICES OFFERED
  210. TABLE 195 QIAGEN: KEY DEVELOPMENTS
  211. TABLE 196 BIO-TECHNE: PRODUCTS AND SERVICES OFFERED
  212. TABLE 197 BIOMÉRIEUX: PRODUCTS AND SERVICES OFFERED
  213. TABLE 198 BIOMÉRIEUX: PRODUCTS OFFERED
  214. TABLE 199 LEICA BIOSYSTEMS NUSSLOCH GMBH: PRODUCTS OFFERED
  215. TABLE 200 LEICA BIOSYSTEMS NUSSLOCH GMBH: PRODUCTS OFFERED
  216. TABLE 201 NG BIOTECH: PRODUCTS OFFERED
  217. TABLE 202 THERMO FISHER SCIENTIFIC INC.: PRODUCTS AND SERVICES OFFERED
  218. TABLE 203 THERMO FISHER SCIENTIFIC INC.: KEY DEVELOPMENTS
  219. TABLE 204 ILLUMINA, INC.: PRODUCTS AND SERVICES OFFERED
  220. TABLE 205 ILLUMINA, INC.: KEY DEVELOPMENTS
  221. TABLE 206 AGILENT TECHNOLOGIES, INC.: PRODUCTS AND SERVICES OFFERED
  222. TABLE 207 AGILENT TECHNOLOGIES, INC.: KEY DEVELOPMENTS
  223. TABLE 208 FOUNDATION MEDICINE INC. (F. HOFFMANN-LA ROCHE LTD ): PRODUCTS AND SERVICES OFFERED
  224. TABLE 209 MYRIAD GENETICS, INC.: PRODUCTS AND SERVICES OFFERED
  225. TABLE 210 MYRIAD GENETICS, INC.: KEY DEVELOPMENTS
  226. LIST OF FIGURES
  227. FIGURE 1 GLOBAL COMPANION DIAGNOSTICS MARKET: STRUCTURE
  228. FIGURE 1 GLOBAL COMPANION DIAGNOSTICS MARKET: MARKET GROWTH AFFECTING FACTOR ANALYSIS (2019-2035)
  229. FIGURE 2 GLOBAL COMPANION DIAGNOSTICS MARKET DRIVER: IMPACT ANALYSIS
  230. FIGURE 3 GLOBAL COMPANION DIAGNOSTICS MARKET RESTRAINT: IMPACT ANALYSIS
  231. FIGURE 4 PORTER'S FIVE FORCES ANALYSIS: GLOBAL COMPANION DIAGNOSTICS MARKET
  232. FIGURE 1 GLOBAL MARKET SHARE ANALYSIS: BY DRUG, 2024
  233. FIGURE 2 NORTH AMERICA MARKET SHARE ANALYSIS: BY DRUG, 2024
  234. FIGURE 3 US MARKET SHARE ANALYSIS: BY DRUG, 2024
  235. FIGURE 4 EUROPE MARKET SHARE ANALYSIS: BY DRUG, 2024
  236. FIGURE 5 GERMANY MARKET SHARE ANALYSIS: BY DRUG, 2024
  237. FIGURE 6 UK MARKET SHARE ANALYSIS: BY DRUG, 2024
  238. FIGURE 7 ASIA-PACIFIC MARKET SHARE ANALYSIS: BY DRUG, 2024
  239. FIGURE 8 CHINA MARKET SHARE ANALYSIS: BY DRUG, 2024
  240. FIGURE 9 INDIA MARKET SHARE ANALYSIS: BY DRUG, 2024
  241. FIGURE 10 JAPAN MARKET SHARE ANALYSIS: BY DRUG, 2024
  242. FIGURE 11 GLOBAL MARKET SHARE ANALYSIS: BY CLONE, 2024
  243. FIGURE 12 NORTH AMERICA MARKET SHARE ANALYSIS: BY CLONE, 2024
  244. FIGURE 13 US MARKET SHARE ANALYSIS: BY CLONE, 2024
  245. FIGURE 14 EUROPE MARKET SHARE ANALYSIS: BY CLONE, 2024
  246. FIGURE 15 GERMANY MARKET SHARE ANALYSIS: BY CLONE, 2024
  247. FIGURE 16 UK MARKET SHARE ANALYSIS: BY CLONE, 2024
  248. FIGURE 17 ASIA-PACIFIC MARKET SHARE ANALYSIS: BY CLONE, 2024
  249. FIGURE 18 INDIA MARKET SHARE ANALYSIS: BY CLONE, 2024
  250. FIGURE 19 JAPAN MARKET SHARE ANALYSIS: BY CLONE, 2024
  251. FIGURE 20 GLOBAL COMPANION DIAGNOSTICS MARKET, TEST TYPE SEGMENT ATTRACTIVENESS, 2024 & 2035 (USD MILLION)
  252. FIGURE 21 GLOBAL COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2024 & 2035 (USD MILLION)
  253. FIGURE 22 GLOBAL COMPANION DIAGNOSTICS MARKET SHARE (%), BY TEST TYPE, 2024
  254. FIGURE 23 GLOBAL COMPANION DIAGNOSTICS MARKET, PRODUCT & SERVICES SEGMENT ATTRACTIVENESS, 2024 & 2035 (USD MILLION)
  255. FIGURE 24 GLOBAL COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICES, 2024 & 2035 (USD MILLION)
  256. FIGURE 25 GLOBAL COMPANION DIAGNOSTICS MARKET SHARE (%), BY PRODUCT & SERVICES, 2024
  257. FIGURE 26 GLOBAL COMPANION DIAGNOSTICS MARKET, TECHNOLOGY SEGMENT ATTRACTIVENESS, 2024 & 2035 (USD MILLION)
  258. FIGURE 27 GLOBAL COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024 & 2035 (USD MILLION)
  259. FIGURE 28 GLOBAL COMPANION DIAGNOSTICS MARKET SHARE (%), BY TECHNOLOGY, 2024
  260. FIGURE 29 GLOBAL COMPANION DIAGNOSTICS MARKET, INDICATION SEGMENT ATTRACTIVENESS, 2024 & 2035 (USD MILLION)
  261. FIGURE 30 GLOBAL COMPANION DIAGNOSTICS MARKET, BY INDICATION 2024 & 2035 (USD MILLION)
  262. FIGURE 31 GLOBAL COMPANION DIAGNOSTICS MARKET SHARE (%), BY INDICATION, 2024
  263. FIGURE 32 GLOBAL COMPANION DIAGNOSTICS MARKET, END USER SEGMENT ATTRACTIVENESS, 2024 & 2035 (USD MILLION)
  264. FIGURE 33 GLOBAL COMPANION DIAGNOSTICS MARKET, BY END USER 2024 & 2035 (USD MILLION)
  265. FIGURE 34 GLOBAL COMPANION DIAGNOSTICS MARKET SHARE (%), BY END USER, 2024
  266. FIGURE 35 GLOBAL COMPANION DIAGNOSTICS MARKET, BY REGION, 2024 & 2035 (USD MILLION)
  267. FIGURE 36 GLOBAL COMPANION DIAGNOSTICS MARKET SHARE (%), BY REGION, 2024
  268. FIGURE 37 NORTH AMERICA MARKET ANALYSIS: COMPANION DIAGNOSTICS MARKET, 2019-2035 (USD MILLION)
  269. FIGURE 38 NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2024 & 2035 (USD MILLION)
  270. FIGURE 39 NORTH AMERICA COMPANION DIAGNOSTICS MARKET SHARE (%), BY COUNTRY, 2024
  271. FIGURE 40 EUROPE MARKET ANALYSIS: COMPANION DIAGNOSTICS MARKET, 2019-2035 (USD MILLION)
  272. FIGURE 41 EUROPE: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2024 & 2035 (USD MILLION)
  273. FIGURE 42 EUROPE: COMPANION DIAGNOSTICS MARKET SHARE (%), BY COUNTRY, 2024
  274. FIGURE 43 ASIA-PACIFIC MARKET ANALYSIS: COMPANION DIAGNOSTICS MARKET, 2019-2035 (USD MILLION)
  275. FIGURE 44 ASIA-PACIFIC MARKET ANALYSIS: COMPANION DIAGNOSTICS MARKET, 2019-2035 (USD MILLION)
  276. FIGURE 45 ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SHARE (%), BY COUNTRY, 2024
  277. FIGURE 46 GLOBAL COMPANION DIAGNOSTICS MARKET PLAYERS: COMPETITIVE ANALYSIS, 2024
  278. FIGURE 47 COMPETITOR DASHBOARD: GLOBAL COMPANION DIAGNOSTICS MARKET
  279. FIGURE 48 QIAGEN: FINANCIAL OVERVIEW SNAPSHOT
  280. FIGURE 49 QIAGEN: SWOT ANALYSIS
  281. FIGURE 50 BIO-TECHNE: FINANCIAL OVERVIEW SNAPSHOT
  282. FIGURE 51 BIO-TECHNE: SWOT ANALYSIS
  283. FIGURE 52 BIOMÉRIEUX: FINANCIAL OVERVIEW SNAPSHOT
  284. FIGURE 53 BIOMÉRIEUX: SWOT ANALYSIS
  285. FIGURE 54 THERMO FISHER SCIENTIFIC INC.: FINANCIAL OVERVIEW SNAPSHOT
  286. FIGURE 55 THERMO FISHER SCIENTIFIC INC.: SWOT ANALYSIS
  287. FIGURE 56 ILLUMINA, INC.: FINANCIAL OVERVIEW SNAPSHOT
  288. FIGURE 57 AGILENT TECHNOLOGIES, INC.: FINANCIAL OVERVIEW SNAPSHOT
    1. Source: Annual Report, Press Releases, And MRFR Analysis
  289. FIGURE 58 AGILENT TECHNOLOGIES, INC.: SWOT ANALYSIS
  290. FIGURE 59 F. HOFFMANN-LA ROCHE LTD (FOUNDATION MEDICINE INC.): FINANCIAL OVERVIEW SNAPSHOT
  291. FIGURE 60 MYRIAD GENETICS, INC.: FINANCIAL OVERVIEW SNAPSHOT

Companion Diagnostics Market Segmentation

  • Companion Diagnostics Market by Test Type Outlook (USD Million, 2019-2035)
  • HER2 Testing
  • PD-1 Testing
  • EGFR Mutation Testing
  • ALK Rearrangement Testing
  • Others
  • Companion Diagnostics Market by Product & Services Outlook (USD Million, 2019-2035)
  • Assays, Reagents & Kits
  • Instruments/Systems
  • Software & Services
  • Companion Diagnostics Market by Technology Outlook (USD Million, 2019-2035)
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Immunohistochemistry (IHC)
  • Fluorescence In Situ Hybridization (FISH)
  • Others
  • Companion Diagnostics Market by Indication Outlook (USD Million, 2019-2035)
  • Cancer
  • Neurological Disorders
  • Cardiovascular Disorders
  • Infectious Diseases
  • Companion Diagnostics Market by End User Outlook (USD Million, 2019-2035)
  • Biopharmaceutical and Biotechnology Companies
  • CROs and CDMOs
  • Others

Companion Diagnostics Market Regional Outlook (USD Million, 2019-2035)

  • North America Outlook (USD Million, 2019-2035)
  • North America Companion Diagnostics Market by Test Type Outlook (USD Million, 2019-2035)
  • HER2 Testing
  • PD-1 Testing
  • EGFR Mutation Testing
  • ALK Rearrangement Testing
  • Others
  • North America Companion Diagnostics Market by Product & Services Outlook (USD Million, 2019-2035)
  • Assays, Reagents & Kits
  • Instruments/Systems
  • Software & Services
  • North America Companion Diagnostics Market by Technology Outlook (USD Million, 2019-2035)
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Immunohistochemistry (IHC)
  • Fluorescence In Situ Hybridization (FISH)
  • Others
  • North America Companion Diagnostics Market by Indication Outlook (USD Million, 2019-2035)
  • Cancer
  • Neurological Disorders
  • Cardiovascular Disorders
  • Infectious Diseases
  • North America Companion Diagnostics Market by End User Outlook (USD Million, 2019-2035)
  • Biopharmaceutical and Biotechnology Companies
  • CROs and CDMOs
  • Others
    • US Outlook (USD Million, 2019-2035)
  • US Companion Diagnostics Market by Test Type Outlook (USD Million, 2019-2035)
  • HER2 Testing
  • PD-1 Testing
  • EGFR Mutation Testing
  • ALK Rearrangement Testing
  • Others
  • US Companion Diagnostics Market by Product & Services Outlook (USD Million, 2019-2035)
  • Assays, Reagents & Kits
  • Instruments/Systems
  • Software & Services
  • US Companion Diagnostics Market by Technology Outlook (USD Million, 2019-2035)
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Immunohistochemistry (IHC)
  • Fluorescence In Situ Hybridization (FISH)
  • Others
  • US Companion Diagnostics Market by Indication Outlook (USD Million, 2019-2035)
  • Cancer
  • Neurological Disorders
  • Cardiovascular Disorders
  • Infectious Diseases
  • US Companion Diagnostics Market by End User Outlook (USD Million, 2019-2035)
  • Biopharmaceutical and Biotechnology Companies
  • CROs and CDMOs
  • Others
    • Canada Outlook (USD Million, 2019-2035)
  • Canada Companion Diagnostics Market by Test Type Outlook (USD Million, 2019-2035)
  • HER2 Testing
  • PD-1 Testing
  • EGFR Mutation Testing
  • ALK Rearrangement Testing
  • Others
  • Canada Companion Diagnostics Market by Product & Services Outlook (USD Million, 2019-2035)
  • Assays, Reagents & Kits
  • Instruments/Systems
  • Software & Services
  • Canada Companion Diagnostics Market by Technology Outlook (USD Million, 2019-2035)
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Immunohistochemistry (IHC)
  • Fluorescence In Situ Hybridization (FISH)
  • Others
  • Canada Companion Diagnostics Market by Indication Outlook (USD Million, 2019-2035)
  • Cancer
  • Neurological Disorders
  • Cardiovascular Disorders
  • Infectious Diseases
  • Canada Companion Diagnostics Market by End User Outlook (USD Million, 2019-2035)
  • Biopharmaceutical and Biotechnology Companies
  • CROs and CDMOs
  • Others
  • Europe Outlook (USD Million, 2019-2035)
  • Europe Companion Diagnostics Market by Test Type Outlook (USD Million, 2019-2035)
  • HER2 Testing
  • PD-1 Testing
  • EGFR Mutation Testing
  • ALK Rearrangement Testing
  • Others
  • Europe Companion Diagnostics Market by Product & Services Outlook (USD Million, 2019-2035)
  • Assays, Reagents & Kits
  • Instruments/Systems
  • Software & Services
  • Europe Companion Diagnostics Market by Technology Outlook (USD Million, 2019-2035)
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Immunohistochemistry (IHC)
  • Fluorescence In Situ Hybridization (FISH)
  • Others
  • Europe Companion Diagnostics Market by Indication Outlook (USD Million, 2019-2035)
  • Cancer
  • Neurological Disorders
  • Cardiovascular Disorders
  • Infectious Diseases
  • Europe Companion Diagnostics Market by End User Outlook (USD Million, 2019-2035)
  • Biopharmaceutical and Biotechnology Companies
  • CROs and CDMOs
  • Others
    • Germany Outlook (USD Million, 2019-2035)
  • Germany Companion Diagnostics Market by Test Type Outlook (USD Million, 2019-2035)
  • HER2 Testing
  • PD-1 Testing
  • EGFR Mutation Testing
  • ALK Rearrangement Testing
  • Others
  • Germany Companion Diagnostics Market by Product & Services Outlook (USD Million, 2019-2035)
  • Assays, Reagents & Kits
  • Instruments/Systems
  • Software & Services
  • Germany Companion Diagnostics Market by Technology Outlook (USD Million, 2019-2035)
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Immunohistochemistry (IHC)
  • Fluorescence In Situ Hybridization (FISH)
  • Others
  • Germany Companion Diagnostics Market by Indication Outlook (USD Million, 2019-2035)
  • Cancer
  • Neurological Disorders
  • Cardiovascular Disorders
  • Infectious Diseases
  • Germany Companion Diagnostics Market by End User Outlook (USD Million, 2019-2035)
  • Biopharmaceutical and Biotechnology Companies
  • CROs and CDMOs
  • Others
    • UK Outlook (USD Million, 2019-2035)
  • UK Companion Diagnostics Market by Test Type Outlook (USD Million, 2019-2035)
  • HER2 Testing
  • PD-1 Testing
  • EGFR Mutation Testing
  • ALK Rearrangement Testing
  • Others
  • UK Companion Diagnostics Market by Product & Services Outlook (USD Million, 2019-2035)
  • Assays, Reagents & Kits
  • Instruments/Systems
  • Software & Services
  • UK Companion Diagnostics Market by Technology Outlook (USD Million, 2019-2035)
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Immunohistochemistry (IHC)
  • Fluorescence In Situ Hybridization (FISH)
  • Others
  • UK Companion Diagnostics Market by Indication Outlook (USD Million, 2019-2035)
  • Cancer
  • Neurological Disorders
  • Cardiovascular Disorders
  • Infectious Diseases
  • UK Companion Diagnostics Market by End User Outlook (USD Million, 2019-2035)
  • Biopharmaceutical and Biotechnology Companies
  • CROs and CDMOs
  • Others

 

  • France Outlook (USD Million, 2019-2035)
  • France Companion Diagnostics Market by Test Type Outlook (USD Million, 2019-2035)
  • HER2 Testing
  • PD-1 Testing
  • EGFR Mutation Testing
  • ALK Rearrangement Testing
  • Others
  • France Companion Diagnostics Market by Product & Services Outlook (USD Million, 2019-2035)
  • Assays, Reagents & Kits
  • Instruments/Systems
  • Software & Services
  • France Companion Diagnostics Market by Technology Outlook (USD Million, 2019-2035)
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Immunohistochemistry (IHC)
  • Fluorescence In Situ Hybridization (FISH)
  • Others
  • France Companion Diagnostics Market by Indication Outlook (USD Million, 2019-2035)
  • Cancer
  • Neurological Disorders
  • Cardiovascular Disorders
  • Infectious Diseases
  • France Companion Diagnostics Market by End User Outlook (USD Million, 2019-2035)
  • Biopharmaceutical and Biotechnology Companies
  • CROs and CDMOs
  • Others
    • Russia Outlook (USD Million, 2019-2035)
  • Russia Companion Diagnostics Market by Test Type Outlook (USD Million, 2019-2035)
  • HER2 Testing
  • PD-1 Testing
  • EGFR Mutation Testing
  • ALK Rearrangement Testing
  • Others
  • Russia Companion Diagnostics Market by Product & Services Outlook (USD Million, 2019-2035)
  • Assays, Reagents & Kits
  • Instruments/Systems
  • Software & Services
  • Russia Companion Diagnostics Market by Technology Outlook (USD Million, 2019-2035)
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Immunohistochemistry (IHC)
  • Fluorescence In Situ Hybridization (FISH)
  • Others
  • Russia Companion Diagnostics Market by Indication Outlook (USD Million, 2019-2035)
  • Cancer
  • Neurological Disorders
  • Cardiovascular Disorders
  • Infectious Diseases
  • Russia Companion Diagnostics Market by End User Outlook (USD Million, 2019-2035)
  • Biopharmaceutical and Biotechnology Companies
  • CROs and CDMOs
  • Others
    • Italy Outlook (USD Million, 2019-2035)
  • Italy Companion Diagnostics Market by Test Type Outlook (USD Million, 2019-2035)
  • HER2 Testing
  • PD-1 Testing
  • EGFR Mutation Testing
  • ALK Rearrangement Testing
  • Others
  • Italy Companion Diagnostics Market by Product & Services Outlook (USD Million, 2019-2035)
  • Assays, Reagents & Kits
  • Instruments/Systems
  • Software & Services
  • Italy Companion Diagnostics Market by Technology Outlook (USD Million, 2019-2035)
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Immunohistochemistry (IHC)
  • Fluorescence In Situ Hybridization (FISH)
  • Others
  • Italy Companion Diagnostics Market by Indication Outlook (USD Million, 2019-2035)
  • Cancer
  • Neurological Disorders
  • Cardiovascular Disorders
  • Infectious Diseases
  • Italy Companion Diagnostics Market by End User Outlook (USD Million, 2019-2035)
  • Biopharmaceutical and Biotechnology Companies
  • CROs and CDMOs
  • Others
    • Spain Outlook (USD Million, 2019-2035)
  • Spain Companion Diagnostics Market by Test Type Outlook (USD Million, 2019-2035)
  • HER2 Testing
  • PD-1 Testing
  • EGFR Mutation Testing
  • ALK Rearrangement Testing
  • Others
  • Spain Companion Diagnostics Market by Product & Services Outlook (USD Million, 2019-2035)
  • Assays, Reagents & Kits
  • Instruments/Systems
  • Software & Services
  • Spain Companion Diagnostics Market by Technology Outlook (USD Million, 2019-2035)
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Immunohistochemistry (IHC)
  • Fluorescence In Situ Hybridization (FISH)
  • Others
  • Spain Companion Diagnostics Market by Indication Outlook (USD Million, 2019-2035)
  • Cancer
  • Neurological Disorders
  • Cardiovascular Disorders
  • Infectious Diseases
  • Spain Companion Diagnostics Market by End User Outlook (USD Million, 2019-2035)
  • Biopharmaceutical and Biotechnology Companies
  • CROs and CDMOs
  • Others
    • Rest Of Europe Outlook (USD Million, 2019-2035)
  • Rest Of Europe Companion Diagnostics Market by Test Type Outlook (USD Million, 2019-2035)
  • HER2 Testing
  • PD-1 Testing
  • EGFR Mutation Testing
  • ALK Rearrangement Testing
  • Others
  • Rest Of Europe Companion Diagnostics Market by Product & Services Outlook (USD Million, 2019-2035)
  • Assays, Reagents & Kits
  • Instruments/Systems
  • Software & Services
  • Rest Of Europe Companion Diagnostics Market by Technology Outlook (USD Million, 2019-2035)
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Immunohistochemistry (IHC)
  • Fluorescence In Situ Hybridization (FISH)
  • Others
  • Rest Of Europe Companion Diagnostics Market by Indication Outlook (USD Million, 2019-2035)
  • Cancer
  • Neurological Disorders
  • Cardiovascular Disorders
  • Infectious Diseases
  • Rest Of Europe Companion Diagnostics Market by End User Outlook (USD Million, 2019-2035)
  • Biopharmaceutical and Biotechnology Companies
  • CROs and CDMOs
  • Others
  • Asia-Pacific Outlook (USD Million, 2019-2035)
  • Asia-Pacific Companion Diagnostics Market by Test Type Outlook (USD Million, 2019-2035)
  • HER2 Testing
  • PD-1 Testing
  • EGFR Mutation Testing
  • ALK Rearrangement Testing
  • Others
  • Asia-Pacific Companion Diagnostics Market by Product & Services Outlook (USD Million, 2019-2035)
  • Assays, Reagents & Kits
  • Instruments/Systems
  • Software & Services
  • Asia-Pacific Companion Diagnostics Market by Technology Outlook (USD Million, 2019-2035)
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Immunohistochemistry (IHC)
  • Fluorescence In Situ Hybridization (FISH)
  • Others
  • Asia-Pacific Companion Diagnostics Market by Indication Outlook (USD Million, 2019-2035)
  • Cancer
  • Neurological Disorders
  • Cardiovascular Disorders
  • Infectious Diseases
  • Asia-Pacific Companion Diagnostics Market by End User Outlook (USD Million, 2019-2035)
  • Biopharmaceutical and Biotechnology Companies
  • CROs and CDMOs
  • Others
    • China Outlook (USD Million, 2019-2035)
  • China Companion Diagnostics Market by Test Type Outlook (USD Million, 2019-2035)
  • HER2 Testing
  • PD-1 Testing
  • EGFR Mutation Testing
  • ALK Rearrangement Testing
  • Others
  • China Companion Diagnostics Market by Product & Services Outlook (USD Million, 2019-2035)
  • Assays, Reagents & Kits
  • Instruments/Systems
  • Software & Services
  • China Companion Diagnostics Market by Technology Outlook (USD Million, 2019-2035)
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Immunohistochemistry (IHC)
  • Fluorescence In Situ Hybridization (FISH)
  • Others
  • China Companion Diagnostics Market by Indication Outlook (USD Million, 2019-2035)
  • Cancer
  • Neurological Disorders
  • Cardiovascular Disorders
  • Infectious Diseases
  • China Companion Diagnostics Market by End User Outlook (USD Million, 2019-2035)
  • Biopharmaceutical and Biotechnology Companies
  • CROs and CDMOs
  • Others
    • India Outlook (USD Million, 2019-2035)
  • India Companion Diagnostics Market by Test Type Outlook (USD Million, 2019-2035)
  • HER2 Testing
  • PD-1 Testing
  • EGFR Mutation Testing
  • ALK Rearrangement Testing
  • Others
  • India Companion Diagnostics Market by Product & Services Outlook (USD Million, 2019-2035)
  • Assays, Reagents & Kits
  • Instruments/Systems
  • Software & Services
  • India Companion Diagnostics Market by Technology Outlook (USD Million, 2019-2035)
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Immunohistochemistry (IHC)
  • Fluorescence In Situ Hybridization (FISH)
  • Others
  • India Companion Diagnostics Market by Indication Outlook (USD Million, 2019-2035)
  • Cancer
  • Neurological Disorders
  • Cardiovascular Disorders
  • Infectious Diseases
  • India Companion Diagnostics Market by End User Outlook (USD Million, 2019-2035)
  • Biopharmaceutical and Biotechnology Companies
  • CROs and CDMOs
  • Others
    • Japan Outlook (USD Million, 2019-2035)
  • Japan Companion Diagnostics Market by Test Type Outlook (USD Million, 2019-2035)
  • HER2 Testing
  • PD-1 Testing
  • EGFR Mutation Testing
  • ALK Rearrangement Testing
  • Others
  • Japan Companion Diagnostics Market by Product & Services Outlook (USD Million, 2019-2035)
  • Assays, Reagents & Kits
  • Instruments/Systems
  • Software & Services
  • Japan Companion Diagnostics Market by Technology Outlook (USD Million, 2019-2035)
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Immunohistochemistry (IHC)
  • Fluorescence In Situ Hybridization (FISH)
  • Others
  • Japan Companion Diagnostics Market by Indication Outlook (USD Million, 2019-2035)
  • Cancer
  • Neurological Disorders
  • Cardiovascular Disorders
  • Infectious Diseases
  • Japan Companion Diagnostics Market by End User Outlook (USD Million, 2019-2035)
  • Biopharmaceutical and Biotechnology Companies
  • CROs and CDMOs
  • Others
    • South Korea Outlook (USD Million, 2019-2035)
  • Global Companion Diagnostics Market by Test Type Outlook (USD Million, 2019-2035)
  • HER2 Testing
  • PD-1 Testing
  • EGFR Mutation Testing
  • ALK Rearrangement Testing
  • Others
  • Global Companion Diagnostics Market by Product & Services Outlook (USD Million, 2019-2035)
  • Assays, Reagents & Kits
  • Instruments/Systems
  • Software & Services
  • Global Companion Diagnostics Market by Technology Outlook (USD Million, 2019-2035)
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Immunohistochemistry (IHC)
  • Fluorescence In Situ Hybridization (FISH)
  • Others
  • Global Companion Diagnostics Market by Indication Outlook (USD Million, 2019-2035)
  • Cancer
  • Neurological Disorders
  • Cardiovascular Disorders
  • Infectious Diseases
  • Global Companion Diagnostics Market by End User Outlook (USD Million, 2019-2035)
  • Biopharmaceutical and Biotechnology Companies
  • CROs and CDMOs
  • Others
    • Rest of Asia-Pacific Outlook (USD Million, 2019-2035)
  • Rest of Asia-Pacific Companion Diagnostics Market by Test Type Outlook (USD Million, 2019-2035)
  • HER2 Testing
  • PD-1 Testing
  • EGFR Mutation Testing
  • ALK Rearrangement Testing
  • Others
  • Rest of Asia-Pacific Companion Diagnostics Market by Product & Services Outlook (USD Million, 2019-2035)
  • Assays, Reagents & Kits
  • Instruments/Systems
  • Software & Services
  • Rest of Asia-Pacific Companion Diagnostics Market by Technology Outlook (USD Million, 2019-2035)
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Immunohistochemistry (IHC)
  • Fluorescence In Situ Hybridization (FISH)
  • Others
  • Rest of Asia-Pacific Companion Diagnostics Market by Indication Outlook (USD Million, 2019-2035)
  • Cancer
  • Neurological Disorders
  • Cardiovascular Disorders
  • Infectious Diseases
  • Rest of Asia-Pacific Companion Diagnostics Market by End User Outlook (USD Million, 2019-2035)
  • Biopharmaceutical and Biotechnology Companies
  • CROs and CDMOs
  • Others

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓